EPS15: A Promising Drug Target and Biomarker for the Treatment of skin Disorders

Target Name: EPS15

NCBI ID: G2060

EPS15

EPS15: A Promising Drug Target and Biomarker for the Treatment of skin Disorders

Epidermal growth factor receptor (EGFR) is a transmembrane protein that plays a crucial role in cell signaling, particularly in the regulation of cell growth, differentiation, and survival. The EGFR gene has four splice variants, isoforms A, B, C, and D, which generate four distinct proteins with distinct functional differences. Of these isoforms, isoform A (EPS15) is the most abundant and widely expressed isoform in human tissues. EPS15 is involved in various cellular processes, including cell adhesion, migration, and angiogenesis, and has been implicated in the development and progression of several skin disorders.

Diseased skin conditions, including skin cancer, neurodermatitis, and wound healing disorders, are a significant public health burden worldwide. The development of new treatments for these conditions is crucial for improving the quality of life and reducing morbidity. EPS15 has emerged as a promising drug target and biomarker for the treatment of skin disorders due to its unique biology and pathological significance.

EPS15 as a Drug Target:

EPS15 is a good candidate for a drug target due to its unique structure and function. Its extracellular domain contains a N-terminal transmembrane domain, a unique GTP-binding site, and a C-terminal tyrosine kinase domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various signaling molecules, including tyrosine kinases and chaperones. The GTP-binding site is a critical region that plays a role in the regulation of protein-protein interactions and signaling. The C-terminal tyrosine kinase domain is responsible for the protein's ability to interact with DNA and regulate gene expression.

Several studies have demonstrated that EPS15 is a potent tyrosine kinase inhibitor. EPS15 has been shown to inhibit the activity of several tyrosine kinases, includingEGFR, PDGFR, and LGR5, in a variety of cell types. These inhibitions lead to the inhibition of cell proliferation, migration, and invasion, which are hallmark features of cancer and neurodegenerative diseases.

EPS15 has also been shown to play a role in the regulation of angiogenesis, a process that is critical for the formation of new blood vessels and the progression of cancer. EPS15 has been shown to promote the migration of blood vessels and cancer cells to new sites of infection or injury, which is a critical step in the development of cancer.

EPS15 as a Biomarker:

EPS15 has also been used as a biomarker for the diagnosis and monitoring of skin disorders. EPS15 is expressed in various tissues and cells of the body, including skin, and has been shown to be involved in the regulation of skin cell growth, differentiation, and survival. Several studies have shown that EPS15 is a sensitive and reliable biomarker for the diagnosis of skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

In addition to its use in cancer diagnosis, EPS15 has also been used as a biomarker for monitoring the efficacy of anti-cancer drugs. The levels of EPS15 have been shown to be reduced in tumors treated with anti-cancer drugs, which suggests that EPS15 may play a role in the development of resistance to these drugs.

EPS15 as a Therapeutic Target:

The inhibition of EPS15 has been shown to be effective in treating several skin disorders, including BCC and SCC. EPS15 has been shown to inhibit the migration and invasion of cancer cells, as well as the formation of new blood vessels that can promote the growth and progression of cancer.

One of the potential advantages of targeting EPS15 is its relatively simple structure, as compared to other tyrosine kinase inhibitors. This allows for the development of small, potent inhibitors that can be easily administered to patients. Additionally, EPS15 has been shown to have a relatively low risk of adverse

Protein Name: Epidermal Growth Factor Receptor Pathway Substrate 15

Functions: Involved in cell growth regulation. May be involved in the regulation of mitogenic signals and control of cell proliferation. Involved in the internalization of ligand-inducible receptors of the receptor tyrosine kinase (RTK) type, in particular EGFR. Plays a role in the assembly of clathrin-coated pits (CCPs). Acts as a clathrin adapter required for post-Golgi trafficking. Seems to be involved in CCPs maturation including invagination or budding. Involved in endocytosis of integrin beta-1 (ITGB1) and transferrin receptor (TFR); internalization of ITGB1 as DAB2-dependent cargo but not TFR seems to require association with DAB2

The "EPS15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPS15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets